Table 3.
Most common treatment-emergent adverse events in advanced-stage Parkinson’s disease (LeWitt 2005)
| Adverse event | Placebo (N=120) | Rotigotine 18.0 mg daily (N=118) | Rotigotine 27.0 mg daily (N=111) |
|---|---|---|---|
| Application and instillation site reactions | 16 (13%) | 43 (36%) | 51 (46%) |
| Application site erythema | 4 (3%) | 24 (20%) | 21 (19%) |
| Application site pruritus | 4 (3%) | 15 (13%) | 21 (19%) |
| Somnolence | 33 (28%) | 38 (32%) | 36 (32%) |
| Nausea | 22 (18%) | 33 (28%) | 24 (22%) |
| Dyskinesia | 8 (7%) | 16 (14%) | 19 (17%) |
| Dizziness | 18 (15%) | 27 (23%) | 17 (15%) |
| Fall | 21 (18%) | 14 (12%) | 17 (15%) |
| Peripheral edema | 1 (<1%) | 11 (9%) | 15 (14%) |
| Insomnia | 7 (6%) | 8 (7%) | 15 (14%) |
| Vomiting | 7 (6%) | 12 (10%) | 9 (8%) |
| Hallucination | 3 (3%) | 4 (3%) | 11 (10%) |
| Arthralgia | 8 (7%) | 13 (11%) | 10 (9%) |
| Headache | 10 (8%) | 12 (10%) | 9 (8%) |